Compare Illumina, Inc. (ILMN) vs Nucor Corporation (NUE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Nucor Corporation — how do they compare? Illumina, Inc. trades at $189.82 (market cap $27.94B), while Nucor Corporation trades at $235.74 (market cap $52.55B). The key difference: Nucor Corporation is the larger of the two by market cap, and Nucor Corporation pays a 0.97% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | NUE | |
|---|---|---|
Market Cap | $27.94B | $52.55B |
Sector | Health | Basic Materials |
52-Week High | $194.33 | $266.35 |
52-Week Low | $91.00 | $131.78 |
Enterprise Value | $29.33B | $57.19B |
Dividend Yield | — | 0.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
Nucor (NUE) trades at $231.86, down 2.01% today, with a bullish technical signal from moving averages and a consensus analyst price target of $263.11. Recent earnings beat expectations in Q1 2026 with EPS of $3.23 versus $2.82 forecast, though Q4 2025 missed. Revenue trends show recovery from $30.7B in 2024 to $32.5B in 2025, with net income margin improving to 6.82% in 2026 projections. The company maintains a strong balance sheet with a debt-to-asset ratio of 20.23% in 2025 and recently announced a joint venture to support AI power infrastructure.
Outlook remains positive driven by higher steel prices and strategic expansions, but risks include cyclical demand weakness and volatile cash flows. Analyst sentiment is bullish with 62.5% buy ratings, supporting potential upside from current levels, though investors should monitor execution on Q2 2026 earnings expected at $4.45 EPS.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →
